1Departmentof Hematology & Oncology, Clinical department of Carlson International Cancer Centre, General Hospital of Shenzhen University, Shenzhen 518000, China；2Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan 430071, Hubei, China； 3Shenzhen University Clinical Medical Academy, Shenzhen 518000, China
Abstract：The degeneration of skeletal muscle is closely related to clinical outcomes of patients with carcinomas. CT is one of the commonly used diagnostic tools for patients with cancers, with high resolutions for skeletal muscles. The CT relevant parameters-SMD （skeletal muscle density） and SMI （skeletal muscle index）-reflect the quality （myosteatosis） and quantity （sarcopenia） for skeletal muscle. In this article, we collected literatures home and abroad through “pubmed and CNKI” to explore the clinical values of SMD and SMI among patients with gastrointestinal cancers. It was found that incidences of myosteatosis （low SMD） and myosteatosis （low SMI） are high, and the evaluation standards are gradually unified. However, the best cut-off value for myosteatosis （low SMD） and myosteatosis （low SMI） is still controversial. Furthermore, both myosteatosis （low SMD） and myosteatosis （low SMI） are associated with poorer treatment tolerance and clinical outcomes. In all, CT relevant parameters provide efficient tools in diagnosis and prognosis prediction for patients with gastrointestinal cancers, with important clinical application value.
1李怡，2周福祥，1李秦阳，1胡科， 1刘先昊，1徐祎骏，1，3于常华. CT相关骨骼肌参数在胃肠道肿瘤中的临床进展[J]. 肿瘤代谢与营养电子杂志, 2019, 6(4): 494-498.
1LI Yi, 2ZHOU Fu-xiang, 1LI Qin-yang, 1 HU Ke, 1LIU Xian-hao, 1XU Yi-jun, 1,3YU Chang-hua. Research progress of CT relevant parameters in patients with gastrointestinal cancers. Electron J Metab Nutr Cancer, 2019, 6(4): 494-498.
1.Miljkovic I, Zmuda JM. Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care. 2010；13（3）:260-264.
2.Brown JC, Caan BJ, Meyerhardt JA, et al. The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study （C-SCANS）. J Cachexia Sarcopenia. 2018；9（4）:664-672.
3.Dijksterhuis WP, Pruijt MJ, Van der Woude SO, et al. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia. 2019；10（1）:199-206.
4.Brown JC, Caan BJ, Meyerhardt JA, et al. The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study （C-SCANS）. J Cachexia Sarcopenia. 2018；9（4）:664-672.
5.Amini B, Boyle SP, Boutin RD, et al. Approaches to assessment of muscle mass and myosteatosis on computed tomography （CT）: a systematic review. J Gerontol A-Biol. 2019；74（10）:1671-1678.
6.Iva M, Zmuda JM. Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care. 2010；13（3）:260-264.
7.Safer U, Binay SV. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016；35（3）:764-764.
8.Amini B, Boyle SP, Boutin RD, et al. Approaches to assessment of muscle mass and myosteatosis on computed tomography: a systematic review. J Gerontol A Biol Sci Med Sci. 2019；74（10）:1671-1678.
9.Van Baar H, Beijer S, Bours MJL, et al. Low radiographic muscle density is associated with lower overall and disease-free survival in early-stage colorectal cancer patients. J Cancer Res Clin Oncola. 2018；144（11）:2139-2147.
10.Martin L, Hopkins J, Malietzis G, et al. Assessment of Computed Tomography （CT）-defined muscle and adipose tissue features in relation to short-term outcomes after elective surgery for colorectal cancer: a multicenter approach. Ann Surg Oncol. 2018；25（9）:1-12.
11.Dijksterhuis WPM, Pruijt MJ, Woude SOVD, et al. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia. 2019；10（1）:199-206.
12.Xiao J, Caan BJ, Weltzien E, et al. Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer. J Cachexia Sarcopenia Muscle. 2018；9（4）:654-663.
13.Baar HV, Beijer S, Bours MJL, et al. Low radiographic muscle density is associated with lower overall and disease-free survival in early-stage colorectal cancer patients. J Cancer Res Clin Oncol. 2018；144（3）:1-9.
14.Van Vugt JLA, Gaspersz MP, Vugts J, et al. Low skeletal muscle density is associated with early death in patients with perihilar cholangiocarcinoma regardless of subsequent treatment. Dig Surg. 2019；36（2）:144-152.
15.Prado CM, Lieffers JR, Mccargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008；9（7）:605-607.
16.Cruz-Jentoft AJ, Jean Pierre B, Bauer JM, et al. Sarcopenia: european consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010；39（4）:412-423.
17.Lisa M, Laura B, Neil M, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013；31（12）:1539-1547.
18.Zhuang CL, Huang DD, Pang WY, et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a Large-Scale Cohort. Medicine. 2016；95（13）:e3164-e3167.
19.Miyamoto Y, Baba Y, Sakamoto Y, et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol. 2015；22（8）:2663-2668.
20.Malietzis G, Currie AC, Athanasiou T, et al. Influence of body composition profile on outcomes following colorectal cancer surgery. Br J Surg. 2016；103（5）:572-580.
21.Fukuda Y, Yamamoto K, Hirao M, et al. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer. 2015；34（3）:S227-S227.
22.Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012；107（6）:931-936.
23.Zhang Y, Wang JP, Wang XL, et al. Computed tomography-quantified body composition predicts short-term outcomes after gastrectomy in gastric cancer. Curr Oncol. 2018；25（5）:e411-e422.
24.Dijksterhuis WPM, Pruijt MJ, Van der Woude SO, et al. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia Muscle. 2019；10（1）:199-206.
25.Tan BHL, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015；41（3）:333-338.
26.Jung H, Kim JW, Kim SW, et al. Effect of muscle mass on toxicity and mortality in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer. 2015；23（3）:687-694.
27.Peng PD, Vledder MG, Van, Susan T, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB （Oxford）. 2011；13（7）:439-446.
28.Kroenke CH, Prado CM, Meyerhardt JA, et al. Muscle radiodensity and mortality in patients with colorectal cancer. Cancer. 2018；124（14）:3008-3015.
29.Charette N, Vandeputte C, Ameye L, et al. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials. BMC Cancer. 2019；19（1）:134-137.
30.Zhuang CL, Shen X, Huang YY, et al. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: a propensity score-matched analysis from a large-scale cohort. Surgery. 2019；166（3）:297-304.
31.Hayashi N, Ando Y, Gyawali B, et al. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. Oncol Rep. 2016；35（3）:1727-1731.
32.Rollins KE, Tewari N, Ackner A, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016；35（5）:1103-1109.
33.Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016；57:58-67.
34.Sueda T, Takahasi H, Nishimura J, et al. Impact of low muscularity and myosteatosis on long-term outcome after curative colorectal cancer surgery: a propensity score-matched analysis. Dis Colon Rectum. 2018；61（3）:1-7.
35.Dohzono S, Sasaoka R, Takamatsu K, et al. Prognostic value of paravertebral muscle density in patients with spinal metastases from gastrointestinal cancer. 2019；27（4）:1207-1213.
